

Conference Highlights featuring ACTC Collaborators

This itinerary lists some of the sessions and posters where ACTC members are either presenting or have co-authored the presentation. We hope this highlights and provides insight into some of the work being done by ACTC members and collaborators.

Sessions are listed in Pacific Standard Time (North America).

Schedule is current at the time of posting. Titles are listed as submitted.

Hybrid sessions are viewed live by both in-person and online attendees, and available to watch online for 30-days. Virtual sessions are viewed live by online attendees, and available to watch online for 30-days.

Sessions featuring ACTC Collaborators as Presenters / Co-Authors

Date and Time	Session Information
Sunday, July 31 11:35am – 11:45am Hybrid	Single-Neuron Genome Sequencing in Alzheimer’s Disease Identifies Disease-Specific Somatic Alterations and Insights into Pathogenesis <i>Matthew Frosch, Bradley Hyman</i>
Sunday, July 31 2:45pm – 3:00pm Hybrid	The rationale behind the NIA-AA research framework definition of Alzheimer's disease <i>Clifford Jack</i>
Monday, August 1 8:00am – 8:15am Hybrid	ALZ-NET: Using Real World Evidence to Inform the Future of Alzheimer's Treatment and Care <i>Gregory Jicha, Oscar Lopez, Anton Porsteinsson, Michael Rafii, Stephen Salloway, Mary Sano</i>
Monday, August 1 12:05pm – 12:15pm Virtual	Amyloid independent pathways have an impact on longitudinal tau deposition <i>Jonathan Graff-Radford, Clifford Jack, Ronald Petersen</i>
Tuesday, August 2 9:25am – 9:35am Hybrid	Participant FIRST: Improving Communication With and Support For Participants in Trials that End Early <i>Sarah Walter</i>
Tuesday, August 2 11:15am – 11:25am Virtual	Comparison of amyloid accumulation between Down syndrome and autosomal-dominant Alzheimer disease <i>Martin Farlow, Neill Graff-Radford, Michael Rafii, Stephen Salloway</i>
Tuesday, August 2 11:25am – 11:35am Virtual	Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration <i>Martin Farlow, Neill Graff-Radford, Clifford Jack, Keith Johnson, Allan Levey, Stephen Salloway, Reisa Sperling</i>

Conference Highlights featuring ACTC Collaborators

Tuesday, August 2 11:55am – 12:05pm Virtual	Defining the ATN framework using longitudinal biomarker trajectories reveals an emerging amyloid accumulation group <i>Michael Donohue, Dorene Rentz, Reisa Sperling</i>
Wednesday, August 3 11:51am – 12:03pm Virtual	Contributions of remote, unsupervised dyadic subjective measures to identify older adults with Mild Cognitive Impairment <i>Ronald Petersen, Michael Weiner</i>
Wednesday, August 3 9:30am – 9:45am Virtual	Plasma ptau231 predicts locus coeruleus integrity earlier in life than other Alzheimer's disease plasma markers: a 7T MRI study across the adult lifespan <i>Keith Johnson, Reisa Sperling</i>
Thursday, August 4 8:40am – 8:50am Hybrid	Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research <i>Neelum Aggarwal, Ganesh Babulal, Nancy Coppelman, Crystal Glover, Lenore Jackson-Pope, Emily Largent, Jennifer Lingler, Aimee Pierce, Dorene Rentz, Sarah Walter</i>
Thursday, August 4 8:20am – 8:30am Hybrid	The Lived Experience Of Latinx-Americans And How Researchers Can Build Stronger Partnerships To Improve Research <i>Sarah Walter</i>
Thursday, August 4 10:35am – 10:45am Virtual	CSF proteomics analysis to investigate the pharmacodynamic response of the S2R modulator CT1812 in Alzheimer's disease patients from the SPARC clinical trial <i>Christopher van Dyck</i>

Posters

Date and Time	Session Information
Sunday, July 31 7:00am – 11:55pm	Measurement invariance of the Cognitive Function Index across race in the A4 study <i>Reisa Sperling</i>
Sunday, July 31 7:00am – 11:55pm	Relation of modifiable lifestyle and mood factors to subjective cognitive concerns among participants and their study partners in the A4 screen data <i>Dorene Rentz, Reisa Sperling</i>
Sunday, July 31 7:00am – 11:55pm	The association between Alzheimer's disease blood-based biomarkers and cognitive impairment and probable dementia in Look AHEAD MIND <i>Doris Molina-Henry</i>
Sunday, July 31 9:15am – 4:45pm	Investigating neurodegenerative heterogeneity in cognitively unimpaired A4 pre-randomization cohort <i>Michael Donohue</i>

Conference Highlights featuring ACTC Collaborators

<p>Sunday, July 31 12:00am – 11:59pm</p>	<p>Strategies for diverse participant recruitment to a preclinical Alzheimer’s Disease prevention trial: The AHEAD study <i>Paul Aisen, Taylor Clanton, Theresa Devins, Shobha Dhadda, Crystal Glover, Joshua Grill, Michael Irizarry, Keith Johnson, Dylan Kim, Lynn Kramer, Doris Molina-Henry, Rema Raman, Leona Shum, Reisa Sperling, Jin Zhou</i></p>
<p>Monday, August 1 12:00am – 11:59pm</p>	<p>Feasibility Study for Detection of Retinal Amyloid in Clinical Trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Trial <i>Robert Rissman</i></p>
<p>Tuesday, August 2 12:00am – 11:59pm</p>	<p>The Institute on Methods and Protocols for Advancement of Clinical Trials for ADRD (IMPACT-AD): An update after two years of conduct <i>Neelum Aggarwal, Paul Aisen, Karen Bell, Tyler Berkness, Jeffrey Burns, Maria Carrillo, Hiroko Dodge, Michael Donohue, Mark Espeland, David Geldmacher, Daniel Gillen, Joshua Grill, Judith Heidebrink, Gregory Jicha, John Olichney, Ronald Petersen, Michael Rafii, Rema Raman, Dorene Rentz, Stephen Salloway, Gopalan Sethuraman, Amanda Smith, Heather Snyder, Reisa Sperling</i></p>
<p>Wednesday, August 3 12:00am – 11:59pm</p>	<p>Evaluation of ethnoracial differences in self- and study partner-reported subjective cognitive decline in the A4 Study screen data <i>Dorene Rentz, Reisa Sperling</i></p>